<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943393</url>
  </required_header>
  <id_info>
    <org_study_id>2034504</org_study_id>
    <nct_id>NCT04943393</nct_id>
  </id_info>
  <brief_title>Remote Neurocognitive and Psychological Assessment in PKU</brief_title>
  <official_title>Remote Assessment of Working Memory and Anxiety in Individuals With Early-Treated Phenylketonuria (PKU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PKU is a rare autosomal recessive condition associated with disruption in dopamine synthesis.&#xD;
      Although early diagnosis and treatment prevent the severe impairments associated with&#xD;
      untreated PKU, individuals with early-treated PKU (ETPKU) nonetheless experience significant&#xD;
      sequelae, including impaired working memory and increased risk for anxiety problems. Past&#xD;
      research with other clinical populations (e.g., generalized anxiety disorder) suggests that&#xD;
      the two phenomena may be linked, with increased anxiety contributing to poorer WM&#xD;
      performance. Currently we propose to initiate an exciting new line of research examining the&#xD;
      potential relationship between anxiety and WM in ETPKU. The proposed study will also apply&#xD;
      remote neuropsychological performance-based assessment to the study of ETPKU and thus&#xD;
      overcoming the geographical limitations/challenges associated with recruitment of&#xD;
      participants with this rare disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Working Memory performance</measure>
    <time_frame>2.5-3 hrs total over approx 1-3 weeks</time_frame>
    <description>Composite score based on multiple working memory-related CANTAB tests</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Phenylketonurias</condition>
  <arm_group>
    <arm_group_label>Individuals with PKU</arm_group_label>
    <description>Adults with early-treated PKU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individuals without PKU</arm_group_label>
    <description>Adults without PKU who are otherwise healthy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nointervention</intervention_name>
    <description>Nointervention</description>
    <arm_group_label>Individuals with PKU</arm_group_label>
    <arm_group_label>Individuals without PKU</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood phe levels&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals age 18-40 years old with and without PKU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with PKU will be included if they were diagnosed as newborns and&#xD;
             immediately started on treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with a history of neurologic compromise or major medical disorder&#xD;
             unrelated to PKU (e.g., closed head injury, diabetes, multiple sclerosis) will be&#xD;
             excluded. In addition, individuals with PKU will be excluded if they are on a&#xD;
             medication called Peg-Valiant/ PEG-PAL/ Pegvaliase/Palynziq.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn Christ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Christ, PhD</last_name>
    <phone>573-884-8140</phone>
    <email>christse@missouri.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rani Singh, PhD, RD, LD</last_name>
      <phone>404-778-8519</phone>
      <email>rsingh@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn Christ, PhD</last_name>
      <phone>573-884-8140</phone>
      <email>christse@missouri.edu</email>
    </contact>
    <investigator>
      <last_name>Shawn Christ, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Shawn Christ</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

